Rapport Therapeutics (RAPP) Accumulated Expenses (2024 - 2026)

Rapport Therapeutics (RAPP) has 3 years of Accumulated Expenses data on file, last reported at $8.7 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 315.68% year-over-year to $8.7 million in Q1 2026; TTM through Mar 2026 was $8.7 million, a 315.68% increase from a year earlier, with the FY2025 full-year figure at $7.1 million, up 92.02% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $8.7 million, up from $7.1 million in the prior quarter.
• Over the last five years, Accumulated Expenses for RAPP reached as high as $8.7 million in Q1 2026 and fell as low as $1.8 million in Q2 2024.
• Historically, Accumulated Expenses has averaged $4.5 million across 3 years, with a median of $3.7 million in 2024.
• Across the five-year window, Accumulated Expenses jumped 64.67% in 2025 and jumped 315.68% in 2026, its largest moves.
• Year by year, Accumulated Expenses stood at $3.7 million in 2024, then jumped by 92.02% to $7.1 million in 2025, then grew by 22.49% to $8.7 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $8.7 million in Q1 2026, $7.1 million in Q4 2025, and $5.0 million in Q3 2025.